Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG415 CAR-T Cells in Relapsed/Refractory Acute Myeloid Leukemia
NCT07668557Phase 1Recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICG415 in acute myeloid leukemia (AML), sponsored by iCell Gene Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 28 days and Treatment-Emergent Adverse Events at 24 months. Started Jun 2026; status: recruiting.
02
Drugs
ICG415
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07668557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668557.